GUMDROP : JHMI J1159 An Open Label, Phase 1 and 2 Safety, Pharmacokinetic, and Proof of Concept Study of ARN 509 in Patients with Progressive Advanced Castration Resistant Prostate Cancer

Created by Channing Paller, last modified by Marte, Jenn (NIH/NCI) [E] on Apr 20, 2012

Description:

This trial measures PSA response to ARN-509 in prostate cancer patients in three cohorts cohorts: (A) non-metastatic castrate resistant prostate cancer (CRPC) with rising PSA and high risk (PSA = 8 ng/mL or PSADT = 10 months); (B) metastatic CRPC with progressive metastatic disease (3 rising PSA, measurable disease, or =2 new bone lesions) treatment-naive; (C) metastatic CRPC with progressive metastatic disease (3 rising PSA, measurable disease, or =2 new bone lesions) chemotherapy naive but previously treated with abiraterone

Link

http://clinicaltrials.gov/ct2/show/NCT01171898

Site:

Johns Hopkins Hospital

Principal Investigator:

Emmanuel Antonarakis, M.D.